Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia.

Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia.
复制标题

急性淋巴细胞白血病中 ARID5B 异常表达及其与 Ikaros 功能障碍的关系

DOI:
10.1038/s41389-018-0095-x
复制
发表时间:
2018-11-12
期刊:
影响因子:
6.2
通讯作者:
Dovat S
Dovat S
中科院分区:
医学1区
文献类型:
--
作者:
Ge Z;Han Q;Gu Y;Ge Q;Ma J;Sloane J;Gao G;Payne KJ;Szekely L;Song C;Dovat S

文献摘要

参考文献

被引文献

相似文献

富含at的相互作用结构域蛋白5B (ARID5B)的突变和单核苷酸多态性参与急性淋巴细胞白血病(ALL)的肿瘤发生和治疗结果。然而,ARID5B在ALL中的表达及其临床意义尚不清楚。我们发现,与健康骨髓对照相比,darid5bis在ALL中显著下调。ARID5B还与PHD指蛋白2 (PHF2)相互作用。在ALL患者中,arid5b (ARID5Blow)或arid5bandphf2 (ARID5BlowPHF2low)的低表达与细胞增殖和不良预后标志物相关。Ikaros直接调控ALL中ARID5B的表达。酪蛋白激酶II抑制恢复Ikaros功能也通过募集组蛋白H3 (H3K4me3)启动子区域赖氨酸4的三甲基化来促进ARID5B的表达。总之,我们的数据表明,ARID5B和PHF2的异常表达与白血病细胞增殖和一些不良预后标志物有关。我们的数据表明,arid5blow表达,特别是arid5blowphf2low表达,与Ikaros功能障碍有关,并参与高风险ALL的致癌作用,这可能代表了ALL的高风险亚组。
Mutations and single nucleotide polymorphisms of AT-rich interactive domain-containing protein 5B (ARID5B) are involved in the oncogenesis of acute lymphoblastic leukemia (ALL) and treatment outcomes. However, ARID5B expression and clinical significance in ALL remain unclear. We foundARID5Bis significantly down-regulated in ALL compared to healthy bone marrow controls. ARID5B also interacts with PHD finger protein 2 (PHF2). Low expression ofARID5B(ARID5Blow) orARID5BandPHF2(ARID5BlowPHF2low) is correlated with the markers of cell proliferation and poor prognosis in ALL patients. Ikaros directly regulates ARID5B expression in ALL. Restoring Ikaros function by Casein Kinase II inhibition also promotes ARID5B expression through recruitment of trimethylation of lysine 4 on histone H3 (H3K4me3) at its promoter region. In summary, our data show that aberrant expression of ARID5B and PHF2 is related to leukemic cell proliferation and several poor prognostic markers. Our data indicate ARID5Blowexpression, particularly ARID5BlowPHF2lowexpression, is linked to Ikaros dysfunction and involved in the oncogenic effect of high-risk ALL, which may represent a high-risk subgroup of ALL.
DOI: 10.4161/adip.25731
发表时间: 2013-10-01
期刊: Adipocyte
影响因子: 3.3
作者:
Okuno Y;Inoue K;Imai Y
通讯作者: Imai Y
DOI: 10.1007/s11010-011-0964-5
发表时间: 2011-10
影响因子: 4.3
作者:
Dovat, Sinisa;Song, Chunhua;Payne, Kimberly J.;Li, Zhanjun
通讯作者: Li, Zhanjun
DOI: 10.1182/blood-2009-08-239681
发表时间: 2010-12-02
期刊: BLOOD
影响因子: 20.3
作者:
Harvey, Richard C.;Mullighan, Charles G.;Willman, Cheryl L.
通讯作者: Willman, Cheryl L.
DOI: 10.1038/onc.2014.219
发表时间: 2015-05-28
期刊: ONCOGENE
影响因子: 8
作者:
Lee, K-H;Park, J-W;Chun, Y-S
通讯作者: Chun, Y-S
通过恢复急性淋巴细胞白血病中的 Ikaros 功能来靶向高 Dynamin-2 (DNM2) 表达。
DOI: 10.1038/srep38004
发表时间: 2016-11-25
期刊: Scientific reports
影响因子: 4.6
作者:
Ge Z;Gu Y;Han Q;Zhao G;Li M;Li J;Chen B;Sun T;Dovat S;Gale RP;Song C
通讯作者: Song C